Besides, HER2-positive BC is very heterogeneous and includes tumors with positive (luminal type) and those with negative (HER2-enriched type) estrogen- (ER) and progesterone- (PgR) hormone receptor status (5). This evidence concerns the gene NR4A1 and breast cancer.